JP2021528059A - グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用 - Google Patents

グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用 Download PDF

Info

Publication number
JP2021528059A
JP2021528059A JP2020569986A JP2020569986A JP2021528059A JP 2021528059 A JP2021528059 A JP 2021528059A JP 2020569986 A JP2020569986 A JP 2020569986A JP 2020569986 A JP2020569986 A JP 2020569986A JP 2021528059 A JP2021528059 A JP 2021528059A
Authority
JP
Japan
Prior art keywords
comp
seq
protein
glycosylation
adp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528059A5 (enExample
Inventor
ハーディング クリスチャン
フェルドマン マリオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Publication of JP2021528059A publication Critical patent/JP2021528059A/ja
Publication of JP2021528059A5 publication Critical patent/JP2021528059A5/ja
Priority to JP2024061674A priority Critical patent/JP2024079845A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020569986A 2018-06-16 2019-06-14 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用 Pending JP2021528059A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024061674A JP2024079845A (ja) 2018-06-16 2024-04-05 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685970P 2018-06-16 2018-06-16
US62/685,970 2018-06-16
US201862783971P 2018-12-21 2018-12-21
US62/783,971 2018-12-21
PCT/US2019/037251 WO2019241672A2 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024061674A Division JP2024079845A (ja) 2018-06-16 2024-04-05 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用

Publications (2)

Publication Number Publication Date
JP2021528059A true JP2021528059A (ja) 2021-10-21
JP2021528059A5 JP2021528059A5 (enExample) 2022-06-22

Family

ID=68843212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569986A Pending JP2021528059A (ja) 2018-06-16 2019-06-14 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
JP2024061674A Pending JP2024079845A (ja) 2018-06-16 2024-04-05 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024061674A Pending JP2024079845A (ja) 2018-06-16 2024-04-05 グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用

Country Status (7)

Country Link
US (2) US11932670B2 (enExample)
EP (1) EP3806881B1 (enExample)
JP (2) JP2021528059A (enExample)
AU (1) AU2019287659B2 (enExample)
CA (1) CA3103474A1 (enExample)
ES (1) ES3051337T3 (enExample)
WO (1) WO2019241672A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3039659T3 (en) 2015-02-26 2025-10-23 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
WO2021259743A2 (en) * 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
US20240066109A1 (en) * 2020-12-31 2024-02-29 Vaxnewmo Llc Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
EP4329796A4 (en) * 2021-04-28 2025-03-19 Vaxnewmo Llc Minimal sequons sufficient for o-linking glycosylation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533511A (ja) * 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2018507693A (ja) * 2015-02-26 2018-03-22 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ アシネトバクター（Ａｃｉｎｅｔｏｂａｃｔｅｒ）Ｏ−オリゴサッカリルトランスフェラーゼおよびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2844831A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
WO2013067523A1 (en) 2011-11-04 2013-05-10 Cornell University A prokaryote-based cell-free system for the synthesis of glycoproteins
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP6356229B2 (ja) 2013-06-04 2018-07-11 アイコン ジェネティクス ゲーエムベーハー 植物産生糖タンパク質及び組換え糖タンパク質のｎ−グリコシル化部位占有率を調節する方法
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
CN107614679B (zh) 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
WO2018135860A1 (ko) 2017-01-17 2018-07-26 포항공과대학교 산학협력단 식물 세포에서의 목적 단백질 발현을 위한 재조합 벡터
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533511A (ja) * 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2018507693A (ja) * 2015-02-26 2018-03-22 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ アシネトバクター（Ａｃｉｎｅｔｏｂａｃｔｅｒ）Ｏ−オリゴサッカリルトランスフェラーゼおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARDING, C. M. ET AL.: "Acinetobacter strains carry two functional oligosaccharyltransferases, one devoted exclusively to ty", MOLECULAR MICROBIOLOGY, vol. 96, no. 5, JPN6023021512, 2015, pages 1023 - 1041, ISSN: 0005070930 *

Also Published As

Publication number Publication date
US12577280B2 (en) 2026-03-17
US20240262870A1 (en) 2024-08-08
WO2019241672A2 (en) 2019-12-19
US11932670B2 (en) 2024-03-19
AU2019287659B2 (en) 2025-02-20
US20210324017A1 (en) 2021-10-21
ES3051337T3 (en) 2025-12-26
EP3806881A2 (en) 2021-04-21
EP3806881B1 (en) 2025-10-08
CA3103474A1 (en) 2019-12-19
WO2019241672A3 (en) 2020-02-06
JP2024079845A (ja) 2024-06-11
AU2019287659A1 (en) 2021-01-07
EP3806881A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
US12577280B2 (en) Glycosylated comp pilin variants, methods of making and uses thereof
AU2019404924B2 (en) O-linked glycosylation recognition motifs
US20190248841A1 (en) Immunogenic Composition
US11819544B2 (en) Immunogenic composition
WO2017067964A1 (en) P. aeruginosa pcrv-linked antigen vaccines
CN111741765A (zh) 免疫原性组合物
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
US12472249B2 (en) Glyconjugate vaccines
US20250381257A1 (en) Vaccine
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
WO2024175620A1 (en) Immunogenic composition
Mayer et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240419

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240517